Pharmacologic drug combination in vagal-induced asystole

• US 6,479,523 B1
• Filed: 08/25/1998
• Issued: 11/12/2002
• Est. Priority Date: 08/26/1997
• Status: Expired due to Term

• Current Assignee: Emory University
• Original Assignee: Emory University
• Inventors: Puskas, John D.
• Primary Examiner(s): MOEZIE, FATEMEH T
• Application Number:
  US09/139,442
• Time in Patent Office: 1,540 Days
• Field of Search: 514/346, 514/652, 514/654, 514/650
• US Class Current: 514/346
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/275 Nitriles; Isonitriles
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/452 Piperidinium derivatives pancuronium A61K31/58
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.

Claims

1. A pharmaceutical composition, comprising an acetylcholinesterase inhibitor, a β

-adrenergic receptor blocker, and a calcium channel blocker.

2. The composition of claim 1, wherein the acetylcholinesterase inhibitor is pyridostygmine bromide.

3. The composition of claim 2, wherein the amount of acetylcholinesterase inhibitor is in the range of about 0.01 mg/kg to about 100.0 mg/kg.

4. The composition of claim 3, wherein the amount of acetylcholinesterase inhibitor is in the range of about 0.1 mg/kg to about 2.0 mg/kg.

5. The composition of claim 1, wherein the β

-adrenergic receptor blocker is propranolol hydrochloride.

6. The composition of claim 5, wherein the amount of β

-adrenergic receptor blocker is in the range of about 0.01 mg/kg to about 100.0 mg/kg.

7. The composition of claim 6, wherein the amount of β

-adrenergic receptor blocker is in the range of about 0.01 mg/kg to about 2.0 mg/kg.

8. The composition of claim 1, wherein the calcium channel blocker is verapamil bromide.

9. The composition of claim 8, wherein the amount of calcium channel blocker is in the range of about 0.001 mg/kg to about 1.0 mg/kg.

10. The composition of claim 9, wherein the amount of calcium channel blocker is in the range of about 0.01 mg/kg to about 0.2 mg/kg.

11. A pharmaceutical composition, comprising an acetylcholinesterase inhibitor, wherein the acetylcholinesterase inhibitor is pyridostigmine bromide, a β

-adrenergic receptor blocker, wherein the β

-adrenergic receptor blocker is propranolol hydrochloride, and a calcium channel blocker, wherein the calcium channel blocker is verapamil bromide.

12. The composition of claim 11, wherein the amount of acetylcholinesterase inhibitor is in the range of about 0.01 mg/kg to about 100.0 mg/kg, wherein the amount of β

-adrenergic receptor blocker is in the range of about 0.01 mg/kg to about 100.0 mg/kg, and wherein the amount of calcium channel blocker is in the range of about 0.001 mg/kg to about 1.0 mg/kg.

13. The composition of claim 12, wherein the amount of acetylcholinesterase inhibitor is in the range of about 0.1 mg/kg to about 2.0 mg/kg, wherein the amount of β

-adrenergic receptor blocker is in the range of about 0.1 mg/kg to about 2.0 mg/kg, and wherein the amount of calcium channel blocker is in the range of about 0.01 mg/kg to about 0.2 mg/kg.

14. A pharmacological composition, comprising an acetylcholinesterase inhibitor, wherein the acetylcholinesterase inhibitor is pyridostigmine bromide at a concentration in the range of about 0.1 mg/kg to about 2.0 mg/kg, a β

-adrenergic receptor blocker, wherein the β

-adrenergic receptor blocker is propranolol hydrochloride at a concentration in the range of about 0.01 mg/kg to about 2.0 mg/kg, and a calcium channel blocker, wherein the calcium channel blocker is verapamil bromide at a concentration in the range of about 0.01 mg/kg to about 0.2 mg/kg.